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The availability of host and dietary carbohydrates in the gastrointestinal (GI) tract plays
a key role in shaping the structure-function of the microbiota. In particular, some gut
bacteria have the ability to forage on glycans provided by the mucus layer covering
the GI tract. The O-glycan structures present in mucin are diverse and complex,
consisting predominantly of core 1-4 mucin-type O-glycans containing α- and β- linked
N-acetyl-galactosamine, galactose and N-acetyl-glucosamine. These core structures
are further elongated and frequently modified by fucose and sialic acid sugar residues
via α1,2/3/4 and α2,3/6 linkages, respectively. The ability to metabolize these mucin
O-linked oligosaccharides is likely to be a key factor in determining which bacterial
species colonize the mucosal surface. Due to their proximity to the immune system,
mucin-degrading bacteria are in a prime location to influence the host response.
However, despite the growing number of bacterial genome sequences available from
mucin degraders, our knowledge on the structural requirements for mucin degradation
by gut bacteria remains fragmented. This is largely due to the limited number of
functionally characterized enzymes and the lack of studies correlating the specificity
of these enzymes with the ability of the strain to degrade and utilize mucin and mucin
glycans. This review focuses on recent findings unraveling the molecular strategies used
by mucin-degrading bacteria to utilize host glycans, adapt to the mucosal environment,
and influence human health.
Keywords: gastrointestinal tract, gut bacteria, intestinal mucus, mucin degradation, O-glycosylation, glycoside
hydrolase, carbohydrate, gut health and disease
Introduction
The human gastrointestinal (GI) tract harbors a complex and dynamic population of microorgan-
isms which contribute significantly to the maintenance of health and the onset and progression
of disease (Sommer and Backhed, 2013). The intestinal epithelium surface is covered by a layer
of mucus which differs in terms of composition, organization, and thickness along the GI tract
Abbreviations: 2′FL, 2-fucosyllactose; 3′FL, 3-fucosyllactose; AgnC, α-N-acetylglucosaminidase; BSM, Bovine submaxillary
mucin; CAZyme, Carbohydrate-active enzyme; CBM, Carbohydrate-binding module; CD, Crohn’s disease; ER, Endoplas-
mic reticulum; Fuc, Fucose; GAG, glycosaminoglycans; Gal, galactose; GalNAc, N-acetyl-galactosamine; GH, Glycoside
hydrolase; GI, gastrointestinal; Glc, Glucose; GlcNAc, N-Acetyl-glucosamine; GNB, Galacto-N-biose; HMO, Human milk
oligosaccharides; IBD, Inflammatory bowel disease; IBS, Irritable bowel syndrome; LNB, Lacto-N-biose; LnbB, Lacto-N-
biosidases; LNFPII, lacto-N-fucopentaose; LNnT, Lacto-N-neo-tetraose; LNT, Lacto-N-tetraose; LPS, Lipopolysaccharide;
MU, 4-Methylumbelliferone; Neu5Ac, N-Acetylneuraminic acid; PGM, Pig gastric mucin; pNP, para-Nitrophenol; pPGM,
Purified pig gastric mucin; PUL, Polysaccharide-utilization loci; Pro, Proline; PTS, Proline-threonine-serine; Ser, Serine; Sus,
Starch utilization system; Thr, Threonine; UC, Ulcerative colitis; VNTR, variable number of tandem repeat.
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(Pullan et al., 1994; Linden et al., 2008; Johansson et al., 2011;
Juge, 2012; Ermund et al., 2013). In the colon, the mucus is
divided into an outer layer which provides a nutrient-rich habitat
for the microbiota and an inner layer firmly attached to the sur-
face of the epithelium, and virtually free of bacteria (Johansson
et al., 2008, 2011). There is an emerging paradigm that mucus is
critical to the maintenance of a homeostatic relationship between
the gut microbiota and their hosts, with subtle deviations from
this dynamic interaction potentially resulting in major implica-
tions for health, among which are colitis, colorectal cancer, and
susceptibility to infection, as extensively reviewed (McGuckin
et al., 2011; Hansson, 2012; Sheng et al., 2012; Chen et al., 2014).
Recent findings showed that alterations in mucosal carbohy-
drate availability impact on the composition of microbial species
(Martens et al., 2008; Ng et al., 2013; Tong et al., 2014). The
mucosal subpopulation is in a prime position to influence host
immune responses. This review is focussed on the nutritional
strategies used by gut bacteria to proliferate into the mucosal
environment.
Mucins and Mucin Glycans of the GI Tract
Intestinal Mucins
Mucins are the main structural components of mucus and play
an integral and multifaceted role in the interaction between
microbes and epithelial surfaces (Linden et al., 2008; Johans-
son et al., 2011). The expression profile of mucins varies among
host tissues and particularly within the GI tract, which dis-
plays the highest and most diverse levels of mucin expression
in the body (Linden et al., 2008). To date, more than 20 genes
encoding mucins have been identified in humans, with their
classification based on the arrangement of their monomeric
polypeptide domains (Corfield, 2014). Mucins are broadly
grouped as membrane-bound or secreted proteins (Moran et al.,
2011; Corfield, 2014) (Table 1). Common to each mucin are an
N-terminal signal peptide and a proline-threonine-serine (PTS)
domain (Figure 1). The signal peptide is required for the tar-
geting of the polypeptide to the endoplasmic reticulum (ER)
and either extracellular secretion or insertion of the synthesized
mucin into the cell membrane. The PTS domain is the site of
extensive O-glycosylation with carbohydrates accounting for up
to 80% of the total mucin mass (Gendler and Spicer, 1995). These
PTS domains, comprised of variable number of tandem repeat
(VNTR) domains, allow for a great degree of heterogeneity in
mucins, due to variability in both, mucin length and extent of
glycan attachment at these sites. This characteristic filamentous
protein backbone decorated with outwardly protruding oligosac-
charides results in the typical “bottle-brush”-like appearance of
mucins (Bergstrom and Xia, 2013).
Membrane-bound mucins are essential contributors of the
glycocalyx of mucosal surfaces where they play important biolog-
ical roles in cell-cell and cell-matrix interactions, and in cell sig-
naling (Jonckheere et al., 2010). These mucins may be shed from
the surface and integrate into the overlying mucus layer where
they are able to influence the viscosity of the protective layer
(Carrington et al., 2009). Secreted mucins are the main structural
components of the mucus gel. Along the GI tract, synthesis and
TABLE 1 | Human membrane-bound and secreted GI mucins.
Type MUC
Gene
Tissue localization
(Detection method)
References
Membrane MUC1 Stomacha
Duodenum, colona,b
Ho et al., 1993;
Buisine et al.,
2000a,b
MUC3A/B Goblet and absorptive
cellsb; Jejunum, ileum
and colona; small
intestinal columnar cells
and surface colonic
epitheliumb
Audie et al., 1993;
Ho et al., 1993;
Chang et al., 1994
MUC4 Stomach and colona Porchet et al., 1995
MUC12 Stomach, small intestine,
and colona
Packer et al., 2004
MUC13 Small intestine and
colona
Packer et al., 2004
MUC15 Small intestine and
colona
Pallesen et al., 2002
MUC17 Stomach, small intestine
(highest expression in
duodenum) and colon
(transverse)a
Gum et al., 2002
MUC20 Colona Higuchi et al., 2004
MUC21 Colona Itoh et al., 2008
Secreted MUC2 Small intestine (jejunum
and ileum) and colona;
Goblet cells of small
intestine and colonb
Audie et al., 1993;
Ho et al., 1993
MUC5AC Stomacha Porchet et al., 1995;
Buisine et al., 2000b
MUC5B Colona (weakly
expressed)
Porchet et al., 1995
MUC6 Stomacha (glands)b,
duodenum (Brunner
glands)b
Buisine et al., 2000b;
Reis et al., 2000;
Nordman et al., 2002
aDetection by gene expression (mRNA expression, Northern blot, or in situ hybridization).
bDetection by immunohistochemistry.
secretion of these polymeric glycoproteins take place in the goblet
cells of the small intestine and colon, or the surface mucous cells
of the stomach (Moncada et al., 2003). Characteristic properties
of the secreted mucins are disulfide bridges which are formed
among the cysteine-rich, cysteine knot, and von Willebrand C
and D domains residing at the N- or C-termini of the glyco-
protein monomers (Desseyn et al., 2008; Ambort et al., 2011)
(Figure 1). MUC2 is the best characterized secreted mucin of the
GI tract (Nilsson et al., 2014). Within the ER, newly synthesized
MUC2 peptides immediately dimerize through the formation
of disulfide bridges followed by transport to the Golgi appara-
tus (Asker et al., 1995, 1998; Ambort et al., 2012b). Here, the
PTS domains of the mucin dimers are sites of elaborate glyco-
sylation before further assembly into trimers in the trans-Golgi
network and packaging into goblet cell vesicles in a pH- and
Ca2+-dependent manner (Godl et al., 2002; Ambort et al., 2012a;
Johansson and Hansson, 2012). As a monomer, fully glycosylated
MUC2 exhibits a large size of approximately 2.5 MDa, while
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FIGURE 1 | Schematic representation of GI mucus and mucins.
The colonic epithelium is protected by mucin glycoproteins which are
either membrane-attached (e.g., MUC1 and MUC4) or are secreted
from goblet cells into the intestinal lumen (e.g., MUC2 and MUC5B).
The secreted mucins further create a protective boundary in the form of
a tightly-adherent mucus layer, which is devoid of bacteria, and a
loosely-adherent mucus layer which provides a niche for intestinal
bacteria.
extensive polymerization may allow for sizes of greater than
100MDa (Johansson et al., 2011). Following secretion of the
mucin granules at themucosal surface, the densely-packedmucin
structures are hydrated and rapidly expand to a size approxi-
mately 3000-fold greater than in the granules, thus providing a
dynamic barrier (Verdugo, 2012).
In addition to their protective and lubricating activities,
mucins facilitate microbial tropism through the presentation of
glycans which may impact colonization (e.g., Kobayashi et al.,
2009; Gonzalez-Rodriguez et al., 2012; Etzold et al., 2014, for a
review see Juge, 2012), and act as a nutritional source formicroor-
ganisms (e.g., Ruas-Madiedo et al., 2008; Crost et al., 2013, for a
review see Marcobal et al., 2013). As such, mucin glycans have
been proposed to play a key role in selecting microbial commu-
nities along and across the GI tract. Consistent with this hypoth-
esis, recent studies in mouse models and humans showed an
association between alteration in mucin glycosylation profile and
deviations of overall community ecology along with altered abun-
dances of specific microbes (Rausch et al., 2011; Wacklin et al.,
2011, 2014; Pacheco et al., 2012; Kashyap et al., 2013; Sommer
et al., 2014).
Mucin Glycosylation
Mucins carry a vast array of oligosaccharide structures, with
the glycosyltransferase profile expressed by the host determining
the type of linkages and glycan structures present on the
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secreted mucins (Linden et al., 2004). The synthesis of mucin
oligosaccharides starts with the transfer of N-acetylgalactosamine
(GalNAc) to Ser and Thr residues of the mucin core (Bennett
et al., 2012). Eight core structures of the mucin O-glycan
chain have been identified (Brockhausen et al., 2009), with
core 1-4 glycans most commonly found in intestinal mucins
(Figure 2A). In humans, gastric and duodenal mucins gen-
erally contain the core 1 (Galβ1–3GalNAcα1-Ser/Thr) and
the core 2 (Galβ1,3(GlcNAcβ1,6)GalNAcα1-Ser/Thr) structures
(Robbe et al., 2004; Larsson et al., 2009), while the core
3 (GlcNAcβ1,3GalNAcαSer/Thr) structure is predominant in
the small intestine (Robbe et al., 2004), and core 3 and 4
(GlcNAcβ1,6(GlcNAcβ1,3)GalNAcαSer/Thr) structures make up
the majority of colonic mucin glycans (Robbe et al., 2004;
Robbe-Masselot et al., 2009; Xia, 2010). Further studies revealed
that MUC2 in the sigmoid colon mainly contains the core 3
structure (Robbe et al., 2004; Thomsson et al., 2012). These
core structures can be further extended with galactose (Gal),
N-acetylglucosamine (GlcNAc), GalNAc, fucose or sialic acid
(Neu5Ac) sugar residues with the latter two frequently occu-
pying terminal positions (Brockhausen et al., 2009). Alterations
in mucin glycosylation have been associated with a number of
diseases such as colitis, colonic cancer and inflammatory bowel
diseases in humans (e.g., McGovern et al., 2010; Larsson et al.,
2011; Rausch et al., 2011; Parmar et al., 2012; Forni et al., 2014)
and mouse models (e.g., An et al., 2007; Stone et al., 2009; Fu
et al., 2011). However, more work is needed to support the causal
link between alteredO-linked glycosylation and inflammation, as
FIGURE 2 | Schematic representation of GI mucin glycans. (A) The four common mucin type O-glycans (core 1-8) found in the GI tract. (B) Main glycan epitopes
in GI mucins. The glycan sugars are represented using Glycan Builder (Ceroni et al., 2007).
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recently reviewed in Theodoratou and colleagues (Theodoratou
et al., 2014).
The main source of glycan diversity is provided by the
peripheral terminal epitopes that show considerable variation
(Figure 2B). The H1 structure (α1,2-fucose) is found in popula-
tions carrying the secretor gene (Mollicone et al., 1985), and indi-
viduals may also express the Lewis gene and the Leb histo-blood
group antigen if they are secretors, while non-secretors express
Lea (Kelly et al., 1995). Another phenotype (SeW—weak secretor)
is characterized by the expression of both Lea and Leb antigens
(Henry et al., 1995; Lindén et al., 2008). The presentation of the
major mucin glycan epitopes, sialic acid and fucose, varies along
the GI tract following opposing gradients with a decreasing gradi-
ent of fucose and ABH blood group expression and an increasing
gradient of sialic acid from the ileum to the colon (Robbe et al.,
2004). Interestingly, these gradients are reversed in mice, where
the small intestine is dominated by sialylated structures and the
colon with those terminating in fucose, potentially creating the
need for additional considerations in the comparison of human
and murine colonization studies (Holmen Larsson et al., 2013).
These terminal mucin O-glycans have been proposed to serve as
metabolic substrates, providing a nutritional advantage to bacte-
ria which have adapted to the GI mucosal environment (Freitas
et al., 2003; Severi et al., 2007; Pacheco et al., 2012; Vimr, 2013).
Conversely, gut bacteria have the ability to affect the mucus bar-
rier (Jakobsson et al., 2015) and mucin glycosylation (Hooper
et al., 1999; Pickard et al., 2014).
Mucin-Degrading Bacteria of the Human
Gut Microbiota
The GI tract is heavily colonized by bacteria with most species
belonging to the phyla Firmicutes, Bacteroidetes, Actinobacteria,
Proteobacteria, and Verrucomicrobia. The microbiota composi-
tion varies longitudinally along the GI tract but also transversally
from the mucosa to the lumen (Zoetendal et al., 2002; Eckburg
et al., 2005; Carroll et al., 2010). Defining the mucosa-associated
bacteria composition is hampered by difficulties in (i) sampling,
limiting the number and power of human studies, (ii) differ-
ences in the nature or definition of the mucosa samples (biopsies,
mucus, or rectal swabs), and (iii) intrinsic inter-individual vari-
ability at the family, genera, or species level (see for example
Hong et al., 2011). However, it is now clear that the composition
of the mucosa-associated microbiota differs from that of the fecal
microbiota in terms of relative abundance of the different phyla,
although the results may vary between studies (Swidsinski et al.,
2005; Frank et al., 2007; Carroll et al., 2010). For example, the
percentage of Bacteroidetes phylum was shown to be higher in
the colonic biopsies or rectal swabs of healthy human volunteers
compared to the feces (Eckburg et al., 2005; Chen et al., 2012).
In contrast, Firmicutes were enriched in the mucosa-associated
bacteria of mice, especially members of the Lachnospiraceae and
Ruminococcaceae families (Nava et al., 2011). Similarly, Van den
Abbeele and collaborators showed that the Firmicutes phylum,
especially members of Clostridium cluster XIVa, was significantly
enriched in the mucus layer as opposed to the lumen, using an
in vitro gutmodel inoculated with human fecal samples (VanDen
Abbeele et al., 2013). These differences may be due to the differ-
ent models used in these studies (e.g., in vivo vs. in vitro; human
vs. mice) and sampling methods. In addition, a number of studies
have focused on specific bacterial groups or species. For example,
sulfate-reducing bacteria, acetogenic bacteria, and methanogenic
archaea were shown to preferentially colonize the healthy human
colon mucosa (Nava et al., 2012). An early study reported that
Lactobacillus gasseri was a predominant Lactobacillus species in
human biopsy samples (Zoetendal et al., 2002) whereas Bifidobac-
terium bifidum and Bifidobacterium longum were shown to be
more abundant in the mucosa of germ-free rats inoculated with
human fecal microbiota than in the lumen (Van Den Abbeele
et al., 2011). Faecalibacterium prausnitzii, an abundant member
of themicrobiota with putative anti-inflammatory properties, has
also been found in ileal, colonic, and rectal biopsies from healthy
individuals (Lopez-Siles et al., 2014).
In the colon, the epithelium is covered by a thick gel of mucus,
divided into two layers, an inner layer firmly attached to the
epithelium and a loose outer layer (Atuma et al., 2001; Ermund
et al., 2013). Johansson and collaborators demonstrated that the
outer mucus layer is heavily colonized by bacteria, while the inner
layer contains no or very few bacteria (Johansson et al., 2008). It is
thus believed that in healthy conditionsmucosa-associated bacte-
ria are not in direct contact with the epithelium but are restricted
to the outer mucus layer. Although the molecular mechanisms
underpinning the adaptation of gut bacteria to mucus remain
unclear, it is likely that their ability to utilize mucin glycans as
a source of nutrients would confer a competitive advantage to
those bacteria with the required repertoire of hydrolytic enzymes.
The first mucin-degrading (or mucinolytic) bacteria studied were
pathogens (e.g., Levy and Aminoff, 1980; Prizont, 1982; Slomi-
any et al., 1992), and thus for a long period mucin degrada-
tion had been associated with pathogenicity. However, it is now
clear that mucin degradation is part of a normal turn-over pro-
cess starting a few months after birth (Norin et al., 1985). To
date, only a limited number of bacterial species/strains from the
Bacteroidetes, Firmicutes, Actinobacteria, and Verrucomicrobia
phyla have been studied for their ability to consume mucins (see
below and Table 2).
The mucin-degrading ability of gut bacteria has been exten-
sively studied in Bacteroidetes. An early study showed that all
22 strains of Bacteroides thetaiotaomicron tested were able to
ferment glycosaminoglycans (GAG) but failed to ferment pig
gastric mucin (PGM) or bovine submaxillary mucin (BSM)
(Salyers et al., 1977a). However, later, B. thetaiotaomicron VPI-
5482 was shown to be able to grow on different fractions
of glycans purified from pig gastric mucosa, including an O-
glycan rich fraction (Martens et al., 2008). Transcriptomic anal-
yses highlighted specific polysaccharide-utilization loci (PULs)
including genes coding for putative glycoside hydrolases (GHs)
such as α-L-fucosidase, endo-β-N-acetylglucosaminidase, endo-
β-galactosidase and α-mannosidase, which were up-regulated
when B. thetaiotaomicron was grown on mucin O-glycans or
in monoxenic mice as compared to in vitro glucose con-
trol. Interestingly, these PULs were not up-regulated when
B. thetaiotaomicron was grown on GAG, as compared to glu-
cose (Martens et al., 2008, 2011). Colonization competition
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TABLE 2 | Mucin-degrading bacteria colonizing the human GI tract.
Bacterial species Strain Mucin tested Enzymatic activitiesa References
B. thetaiotaomicron VPI-5482 = ATCC 29148 Purified O-glycans from
PGM type III
α-L-fucosidase;
endo-β-N-acetylglucosaminidase;
endo-β-galactosidase; α-mannosidase
Martens et al., 2008
B. fragilis 2 strains BSM Unknown Salyers et al., 1977a
ATCC 23745 PGM; pig colonic mucin Unknown Roberton and Stanley, 1982
ATCC 25285 PGM; pig colonic mucin Unknown Roberton and Stanley, 1982
Purified O-glycans from
PGM type III
Sialidase Marcobal et al., 2011
B. vulgatus VIII-271F pPGM* Unknown Hoskins et al., 1992
ATCC 8482 pPGM type II Unknown Png et al., 2010
Bacteroides caccae 1 strain BSM Unknown Salyers et al., 1977a
A. muciniphila ATCC BAA-835 pPGM type III α-galactosidase; β-galactosidase;
α-L-fucosidase; β-glucosidase;
α-mannosidase; α-galactosidase;
β-D-fucosidase;
α-N-acetylgalactosaminidase;
β-N-acetylgalactosaminidase;
β-N-acetylglucosaminidase; sulfatase
Derrien et al., 2004; Derrien,
2007
pPGM type II; human MUC2 Unknown Png et al., 2010
R. gnavus ATCC 29149 pPGM type II; human MUC2 Unknown Png et al., 2010
pPGM type III α-L-fucosidase; α2,3-sialidase Crost et al., 2013
ATCC 35913 = VI-268 pPGM* Blood group B-degrading activity; blood
group H-degrading activity; sialidase;
β-galactosidase; sialate
O-acetylesterase
Hoskins et al., 1985;
Corfield et al., 1992
pPGM type III Unknown
R. torques IX-70 = ATCC 35915 pPGM* Blood group A-degrading activity; blood
group H-degrading activity; sialidase;
β-galactosidase;
β-N-acetylgalactosaminidase;
β-N-acetylglucosaminidase; sialate
O-acetylesterase; glycosulfatase
Hoskins et al., 1985;
Corfield et al., 1992;
Hoskins et al., 1992
VIII-239 pPGM* Same as for strain IX-70 Hoskins et al., 1985;
Corfield et al., 1992;
Hoskins et al., 1992
ATCC 27756 pPGM type II; human MUC2 Unknown Png et al., 2010
B. bifidum D119 PGM type III Unknown Ruas-Madiedo et al., 2008;
Turroni et al., 2010
L22 PGM type III endo-α-N-acetylgalactosaminidase;
α1,2-L-fucosidase
Ruas-Madiedo et al., 2008;
Turroni et al., 2010
VIII-210 = ATCC 35914 pPGM* Blood group H-degrading activity;
sialidase; β-galactosidase;
β-N-acetylgalactosaminidase;
β-N-acetylglucosaminidase; sialate
O-acetylesterase; glycosulfatase
Hoskins et al., 1985;
Corfield et al., 1992;
Hoskins et al., 1992
pPGM type II; human MUC2 Unknown Png et al., 2010
PLR2010 PGM type III α1,2-L-fucosidase; α1,3/4-L-fucosidase;
exo-α-sialidases;
α-L-arabinofuranosidase;
α1,3-galactosidase;
endo-α-N-acetylgalactosaminidase;
β-N-acetylhexosaminidases;
β-galactosidase
Turroni et al., 2010
A8 Unknown Turroni et al., 2010
(Continued)
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TABLE 2 | Continued
Bacterial species Strain Mucin tested Enzymatic activitiesa References
324B Unknown Turroni et al., 2010
156B Unknown Turroni et al., 2010
85B Unknown Turroni et al., 2010
DSM 20456 Unknown Turroni et al., 2010
B. longum subsp.
longum
NCIMB8809 PGM type III Unknown Ruas-Madiedo et al., 2008
Human intestinal mucus β-N-acetylglucosaminidase;
β-glucuronidase
Ruiz et al., 2011
B. longum subsp.
infantis
VIII-240 pPGM* Blood group H-degrading activity;
sialidase; β-galactosidase;
β-N-acetylgalactosaminidase;
β-N-acetylglucosaminidase; sialate
O-acetylesterase; glycosulfatase
Hoskins et al., 1985;
Corfield et al., 1992;
Hoskins et al., 1992
ATCC 15697 PGM type III Unknown Turroni et al., 2010; Kim
et al., 2013
B. breve NCIMB8807 PGM type III Unknown Ruas-Madiedo et al., 2008
PGM, pig gastric mucin (Sigma-Aldrich).
PGM*, pig gastric mucin (ICN Nutritional Biochemicals).
pPGM, purified PGM, purified according to Miller and Hoskins’ method (Miller and Hoskins, 1981).
BSM, bovine submaxillary mucin (Sigma-Aldrich).
aEnzymatic activities putatively involved in mucin degradation were identified by (i) activity assays using the spent media, (ii) activity assays using the lysed cells or (iii) transcriptomic
assay, when the bacterium was grown with mucin.
experiments demonstrated that B. thetaiotaomicron mutants for
O-glycan PULs were able to colonize germ-free mice in a similar
way as the wild-type strain when mice were fed a plant glycan-
rich diet, but were outcompeted by the wild-type on a simple-
sugar diet (Martens et al., 2008). This indicates that B. thetaio-
taomicron relies on mucin and other host-derived glycans for
colonization. Genome analysis of Bacteroides fragilis confirmed
that Bacteroides species contain a much larger number of genes
encoding carbohydrate-active enzymes (CAZymes) compared to
other sequenced gut bacteria (Kuwahara et al., 2004). In accor-
dance with early studies demonstrating the ability of some B. frag-
ilis strains to grow on mucin as sole carbon source (Salyers et al.,
1977a; Roberton and Stanley, 1982), the B. fragilis genome con-
tains a subset of PULs dedicated to host mucin O-glycan utiliza-
tion; in particular, it has been shown that (i) loci involved in the
binding, degradation, and transport of sialylated polysaccharides
play an important role in the colonization of this bacterium in the
gut (Nakayama-Imaohji et al., 2012) and (ii) the genes involved in
sialic acid utilization are up-regulated when B. fragilis is grown in
the presence of mucin O-glycans as compared to glucose (Mar-
cobal et al., 2011). Some strains of Bacteroides vulgatus have also
been shown to moderately degrade PGM but failed to utilize
human MUC2 (Hoskins et al., 1992; Png et al., 2010) (Table 2).
In the Firmicutes phylum, Ruminococcus torques and
Ruminococcus gnavus, both members of the Lachnospiraceae
family (belonging to the C. coccoides group/cluster XIVa) have
been shown to degrade mucins. In an early study, six R. torques
strains out of nine tested, but none of the R. gnavus strains
tested, were shown to have the capacity to ferment PGM (Salyers
et al., 1977b). A few years later, R. gnavus ATCC 35913 and two
R. torques strains (ATCC 35915 and VIII-239) were among the
five strains isolated from human fecal samples for their ability to
degrademucins (Hoskins et al., 1985). Png and collaborators then
confirmed that both R. gnavus and R. torques species were able to
degrade and utilize human MUC2 as a sole carbon source (Png
et al., 2010), providing further evidence of their adaptation to the
human colonic mucosal environment. Several enzymatic activi-
ties were detected in the spent media of these strains grown with
mucin that could explain their ability to degrade mucin (Hoskins
et al., 1985, 1992; Corfield et al., 1992; Crost et al., 2013) (Table 2).
Recently, the ability of R. gnavus strains to utilize mucin was
shown to be strain-dependent, as also supported by comparative
genomic and transcriptomic analyses (Crost et al., 2013), and in
agreement with earlier findings (Salyers et al., 1977b).
B. bifidum ATCC 35914 and B. longum subsp. infantis VIII-
240, from the Actinobacteria phylum, were also isolated by
Hoskins and collaborators (Hoskins et al., 1985) as mucin
degraders, and several enzymatic activities possibly involved
in mucin degradation were detected in the spent media of
these strains grown with mucin as sole carbon source (Hoskins
et al., 1985, 1992; Corfield et al., 1992) (Table 2). Since then, B.
longum subsp. infantis has been shown to grow on mucins, albeit
moderately (Abe et al., 2010; Turroni et al., 2010; Kim et al.,
2013), and the ability of B. bifidum to utilize mucins has been
confirmed for several strains using different types of mucins,
including human MUC2 (Ruas-Madiedo et al., 2008; Png et al.,
2010; Turroni et al., 2010) (Table 2). Transcriptomic analyses of
B. bifidum L22 and PLR2010 suggest the involvement of sev-
eral enzymes in the process, e.g., α-L-fucosidase and endo-α-
N-acetylgalactosaminidase (Ruas-Madiedo et al., 2008; Turroni
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et al., 2010) (Table 2). Few other Bifidobacteria species, includ-
ing some strains of B. longum subsp. longum and Bifidobacterium
breve, have also been shown to degrade mucins in vitro (Ruas-
Madiedo et al., 2008; Turroni et al., 2010; Ruiz et al., 2011)
(Table 2). β-N-acetylglucosaminidase and β-glucuronidase activ-
ities were increased in the spent medium of B. longum subsp.
longum NCIMB8809 grown with human intestinal mucus, sug-
gesting a role of these activities in mucin degradation. More
recently, detailed genome analyses of Bifidobacteria have iden-
tified metabolic pathways for the degradation of mucin-type O-
glycans and human milk oligosaccharides (HMOs) (Sela et al.,
2008; Turroni et al., 2010) and several GHs have been functionally
characterized supporting these findings (Yamamoto et al., 2010;
Kiyohara et al., 2011) (see section below).
In the Verrucomicrobia phylum, Akkermansia muciniphila, a
strictly anaerobic Gram-negative bacterial species, was recently
identified as a key mucin degrader (Derrien et al., 2004). Initially
isolated from a human fecal sample due to its ability to utilize
mucins as sole carbon and nitrogen source, A. muciniphila has
since been shown to be a common member of the human gut
with a high prevalence and variable abundance, present both in
feces and at the mucosal surface (Eckburg et al., 2005; Collado
et al., 2007; Derrien et al., 2008). When A. muciniphila ATCC
BAA-835 was grown with mucin as sole carbon source, sev-
eral enzymatic activities potentially involved in mucin degrada-
tion were detected both in the spent medium and intracellularly
(Derrien, 2007). However, although numerous genes encoding
putative mucinolytic enzymes were found in the genome of the
ATCC BAA-835 strain (Van Passel et al., 2011), the functional
characterization of these proteins, and thus their role in mucin
degradation, has not yet been reported.
Bacterial Enzymes Involved in Mucin
Degradation
Given the diversity and complexity of intestinal mucin glycan
structures, strategies for deconstructing these molecules rely on
the cooperative action of a number of proteases, sulfatases, and
GHs encoded by the genome of mucin-degrading bacteria. These
GHs include, but are not limited to, neuraminidases/sialidases
(GH33), fucosidases (GH29 and GH95), exo- and endo-β-N-
acetylglucosaminidases (GH84 and GH85), β-galactosidases
(GH2, GH20, and GH42), α-N-acetylglucosaminidases
(GH89), and α-N-acetylgalactosaminidases (GH101, GH129)
(www.cazy.org/) (Lombard et al., 2014) (Figure 3 and Table S1).
However, in sharp contrast to the number of genes predicted
to be involved in mucin degradation (mainly based on tran-
scriptomic analyses), only a few GHs have been biochemically
characterized (see CAZy database; www.cazy.org). Detailed enzy-
matic characterization of putative mucin-degrading enzymes,
and CAZymes in general, is essential for allowing accurate anno-
tation of homologous gene sequences. Indeed, the process of reli-
able annotation of protein function from gene sequence is one
of the main challenges for the effective use of metaproteomic
data from the human microbiota (Kolmeder and De Vos, 2014).
Currently, 46 bacterial GHs involved in mucin degradation have
been functionally characterized, either by recombinant means,
following identification of putative target genes by genomic anal-
ysis, or by purifying the bacterial enzyme following an activity
screening (Table S1). Given the large diversity and complexity of
mucin glycosylation, and the lack of amenable sources of mucins,
functional characterization of mucin-degrading GHs often relies
on the use of mucin-type oligosaccharides or synthetic substrates
(such as para-Nitrophenol (pNP)- or 4-Methylumbelliferone
(MU)-derivatized glycans) as surrogate substrates (Table S1).
Owing to the paucity of purified proteins, only limited struc-
tural information is available on mucin-degrading enzymes from
human gut bacteria, e.g., the absence of a GH129 crystal structure
(www.cazy.org).
In addition to their catalytic domains, GHs may have one
or more carbohydrate binding modules (CBMs) which medi-
ate the adherence of CAZymes to their carbohydrate sub-
strate. Currently, CBMs that recognize mucin glycans have
been reported in families 32, 40, 47, and 51, as reviewed in
Ficko-Blean and Boraston (2012a). These CBMs show speci-
ficity for terminal glycan motifs, such as Gal, GlcNAc, sialic acid,
fucose, and histo-blood group antigens (Etzold and Juge, 2014).
Other non-catalytic domains associated with these GHs include
immunoglobulin domains, concanavalin A domains, or domains
of unknown function (Table S1).
The genomic organization of mucin-degrading enzymes has
been studied in few bacterial species. Bacteroidetes employ a
highly organized system for glycan utilization whereby all genes
involved in the degradation of dietary- or host-derived carbo-
hydrate (GHs, sugar transport proteins, sugar sensors, regula-
tory proteins, etc.) are grouped together in a single PUL, as
recently reviewed in Martens et al. (2009). Starch utilization sys-
tems (Sus) or Sus-like proteins have been particularly well stud-
ied in B. thetaiotaomicron (Martens et al., 2009). SusD proteins
are cell envelope-associated proteins that mediate glycan bind-
ing, and a SusD like protein BT1043 of B. thetaiotaomicron has
been implicated in O-glycan utilization of host mucins (Martens
et al., 2008). Recently, the sialic acid utilizing protein NanU, a
SusD family protein from B. fragilis, has been demonstrated to
bind Neu5Ac with high affinity (Phansopa et al., 2014). Such
organization in PULs is less apparent in Firmicutes. Generally
the genes involved in the utilization of particular mucin gly-
cans are clustered together in operons. For example, sialidases
are often found in a cluster with other proteins involved in
sialic acid catabolism (see below), and B. longum subsp. infan-
tis has clusters dedicated to the metabolism of HMOs which
share structural similarities with mucin core glycans (Sela et al.,
2008).
Sialic Acid Metabolism
The release of sialic acid from non-reducing ends is an ini-
tial step in the sequential degradation of mucins since the
terminal location of sialic acid residues in the mucin oligosac-
charide chains may prevent the action of other GHs. In
bacteria, the genes involved in sialic acid metabolism are usu-
ally found clustered together forming what is denominated
as a Nan cluster. Human gut bacteria that encode a Nan
cluster include R. gnavus, Anaerotruncus colihominis, Dorea
formicigenerans, Dorea longicatena, F. prausnitzii, Fusobacterium
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FIGURE 3 | O-glycan chains showing sites of action of GHs and sulfatases. Chain 1 is a hypothetical mucin glycan chain, chain 2 is O-GlcNAc often found on
other glycoproteins, chain 3 (Tn antigen) and chain 4 are found in gastro-duodenal mucin.
nucleatum, Lactobacillus sakei, Lactobacillus plantarum, and
Lactobacillus salivarius (Almagro-Moreno and Boyd, 2009),
B. fragilis (Brigham et al., 2009), and B. breve (Egan et al., 2014).
Thus, the majority of the bacteria that harbor a Nan cluster col-
onize mucus regions of the human body, such as the gut, lung,
bladder, or oral cavity, where sialic acid is highly abundant and
can serve as a source of energy, carbon, and nitrogen (Almagro-
Moreno and Boyd, 2009). However, some bacteria appear to have
incomplete packages of enzymes for utilizing host sialic acids.
For example, B. thetaiotaomicron encodes a sialidase and can
release free sialic acid, but lacks the Nan operon required to con-
sume the liberated monosaccharide and does not appear capa-
ble of consuming free sialic acid (Marcobal et al., 2011). On
the other hand, Salmonella typhimurium and Clostridium diffi-
cile encode the Nan operon but each lacks the sialidase (Hoyer
et al., 1992; Sebaihia et al., 2006), and thus rely on other sialidase-
producing organisms to acquire this potential nutrient source
from the mucosal environment (Vimr et al., 2004; Ng et al.,
2013).
GH33 sialidases encoded by human gut bacteria vary in
terms of their substrate specificity and enzymatic reaction.
Although most of them are hydrolytic sialidases, releasing sialic
acid from sialylated substrates, some display transglycosyla-
tion activities (see Table S1). For example the sialidase from
B. bifidum JCM 1254 can transfer Neu5Ac to 1-alkanols, that
of R. gnavus ATCC 29149 (RgNanH) is an intramolecular
trans-sialidase (IT-sialidase) which releases 2,7 anhydro-Neu5Ac
specifically from α2,3-linked sialyl conjugates (Crost et al., 2013),
and NanI from Clostridium perfringens str 13 can hydrate
the inhibitor 2-deoxy-2,3-dehydro-Neu5Ac to Neu5Ac (New-
stead et al., 2008). Trans-sialidases show specificity for α2,3
linkages, whereas hydrolytic sialidases can often cleave α2,3,
2,6, or 2,8 linkages (e.g., B. thetaiotaomicron sialidase BTSA).
However, the substrate specificity of many sialidases remains
unknown as MU-Neu5Ac is often the only tested substrate
(Table S1). Furthermore, few of these purified sialidases have
been enzymatically characterized using mucin as a natural
substrate (Table S1). Sialidases have been identified in the
genomes of infant-derived Bifidobacteria, including two intra-
cellular sialidases from B. longum subsp. infantis ATCC 15697
(Sela et al., 2008), two predicted extracellular exo-α-sialidases
of B. bifidum PRL 2010 (Turroni et al., 2010), and a puta-
tive sialidase from B. breve (Egan et al., 2014). However, the
only sialidase from this group of infant-associated bacteria to
be functionally characterized is SiaBb2 from B. bifidum JCM
1254, a strain for which the genome sequence is not yet pub-
licly available. SiaBb2 has a strong preference for α2,6 link-
ages and was shown to be sufficient to confer B. longum
105-A with the ability to degrade HMOs (Kiyohara et al.,
2011).
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Fucose Metabolism
In mucins, fucosyl residues can be found at the extremity of
the O-glycosidic chain linked to galactose by α1,2 linkages or to
GlcNAc by α1,3 linkages, whereas it is most commonly linked
α1,6 to the reducing, terminal β-GlcNAc in human N-linked gly-
cans. Fucosidase-encoding genes are widely distributed in the
genome of gut bacteria and generally belong to GH29 and GH95
families, which differ in their enzymatic mechanisms; GH29
enzymes retain the anomeric conformation of the glycosidic
bond (Katayama et al., 2005) whereas GH95 enzymes proceed
via the inverting mechanism (Nagae et al., 2007). Transcriptional
data suggest that GH29 and GH95 fucosidases play a key role in
the ability of B. thetaiotaomicronVPI-5482 (Martens et al., 2008),
B. longum subspecies infantis ATCC 15697 (Sela et al., 2012),
B. bifidum JCM 1254 (Ashida et al., 2009), and R. gnavus ATCC
29149 (Crost et al., 2013) to utilize mucins as a source of car-
bon. However, the enzymatic characterization of members of the
GH95 and GH29 family is often hampered by the fact that most
of these enzymes are not active against synthetic fucosyl conju-
gates (Katayama et al., 2005), preventing high throughput activity
screening. It is notable that among 495 bacterial GH95 enzymes
being listed in the CAZy database to date (02 October 2014), only
two have been biochemically characterized, one from B. longum
subspecies infantis ATCC 15697 and one from B. bifidum
JCM 1254 (Table S1), both from human gut commensal
strains.
The substrate specificity of GH29 and GH95 fucosidases
has been predominantly characterized in B. bifidum JCM 1254,
where GH95 AfcA was shown to be specific for α1,2 linkages
(Katayama et al., 2005) and GH29 AfcB for α1,3 and α1,4
linkages (Ashida et al., 2009); together these enzymes can remove
fucose at the non-reducing termini except for those that are
α1,6-linked (Ashida et al., 2009). AfcA and AfcB have been
shown to be sufficient to confer B. longum 105-A with the
ability to grow on 2-fucosyllactose (2′FL), 3-fucosyllactose (3′FL)
and lacto-N-fucopentaose (LNFPII) (Ashida et al., 2009). The
structural basis for the specificity of AfcA has been determined
(Nagae et al., 2007).
B. thetaiotaomicron produces multiple fucosidases that cleave
fucose from host glycans, resulting in high fucose availability
in the gut lumen (Xu et al., 2003). The genome of B. thetaio-
taomicron VPI-5482 encodes five GH95 and nine GH29 genes
(www.cazy.org). Two of the GH29 genes have been expressed
and shown to have α-fucosidase activity and have been clas-
sified in separate sub-families, i.e., GH29-A (BT_2970) has a
relaxed specificity that can accommodate pNP-fucose (pNP-
Fuc), whereas GH29-B (BT_2192) is specific for branched fuco-
oligosaccharides found in Lewis blood groups (also present in
mucin structures, see Figure 2B) (Sakurama et al., 2012) (Table
S1). The structural basis for this specificity between the two
B. thetaiotaomicron fucosidases was first expounded by Sakurama
et al. (2012) using the structures from BT_2970 (GH29-A),
(Lammerts Van Bueren et al., 2010) and BT_2192 (GH29-B)
(PDB 3EYP, http://www.rcsb.org). Further structural analysis of
BT_2192 elucidated the molecular mechanisms for the binding
of the branched oligosaccharides and the unusual dual specificity
of this enzyme, which also acts as a β-galactosidase (Guillotin
et al., 2014). More detailed analysis of the substrate specificity of
fucosidases is warranted to determine why B. thetaiotaomicron,
and indeed other resident members of the human microbiota,
have evolved to produce multiple α-fucosidases.
Blood Group Metabolism
Both the blood group A antigen and B antigen can be cleaved
from mucin by GH98 endo-β1,4-galactosidases, these have been
characterized in Clostridium perfringens strains 10543 and 13
(Anderson et al., 2005; Table S1; Figure 3). The only structural
information about this family of enzymes comes from Strep-
tococcus pneumoniae str. and reveals a (α/β)8 barrel (Higgins
et al., 2009). Once the terminal sugars and blood group anti-
gens are removed, the mucin core glycans are exposed to further
enzymatic degradation.
Mucin Glycan Core Metabolism
Mucin glycan core structures are cleaved from the Ser/Thr
amino acids of the mucin protein backbone by endo-α-N-
acetylgalactosaminidases, with that of B. bifidum (EndoBF) being
the founding member of GH101 (Fujita et al., 2005). These
enzymes differ in their specificity toward core glycan structure
types (Table S1). For example, EndoBF is specific for the core 1
glycan (Galβ1,3GalNAc) (Katayama et al., 2005) while endo-α-N-
acetylgalactosaminidases from Enterococcus faecalis and C. per-
fringens have a broader specificity (Ashida et al., 2008; Goda et al.,
2008; Koutsioulis et al., 2008). The structural basis for this speci-
ficity has been elucidated for EndoBF (Suzuki et al., 2009). The
α-N-acetylgalactosaminidase from B. bifidum JCM 1254 is the
founding member of GH129 and differs from GH101 in that it
targets the Tn antigen (GalNAcα1-Ser) found in gastroduodenal
mucins (Kiyohara et al., 2012). GH129 is a small family with only
58 members to date (02 Oct 14), all of which are of bacterial ori-
gin. Many of the species encoding a GH129 are associated with
the infant microbiota (Kiyohara et al., 2012), although Bacillus
sp. also contain GH129 (www.cazy.org).
GH2, GH20, and GH42 β-galactosidases have been impli-
cated in the degradation of type-1 and type-2 HMOs. Genome
analysis of several Bifidobacteria species identified common
metabolic pathways for the degradation of lacto-N-biose I
(Galβ1,3GlcNAc, LNB) and galacto-N-biose (Galβ1,3GalNAc,
GNB), a building block of the core 1 structure of mucin-
type O-glycan, whereas the degradation of type-2 lacto-N-neo-
tetraose (Galβ1,4GlcNAcβ1,3Galβ1,4Glc, LNnT), also present in
the core 2 mucin-type O-glycans, involves a different pathway.
In Bifidobacteria, the type-1 chain (Galβ1,3GlcNAcβ1-) is likely
eliminated by GH20 lacto-N-biosidases (LnbB) (Wada et al.,
2008), and the released LNB incorporated into the cytosol via a
GNB/LNB transporter (Suzuki et al., 2009). Despite the quite rare
occurrence in nature of β-galactosidases acting on type-1 chains,
close lacto-N-biosidase homologs are present in the genomes
of infant-gut associated Bifidobacteria that are known to con-
sume type 1 Lacto-N-tetraose (Galβ1,3GlcNAcβ1,3Galβ1,4Glc,
LNT), these are the GH42 LNT β-galactosidases (Yoshida et al.,
2012). In Bifidobacteria, the type-2 chain (Galβ1,4GlcNAcβ1-)
is sequentially degraded by GH2 β-galactosidase, BbgIII, acting
on LacNAc and GH20 β-N-acetylhexosaminidases, BbhI and
Frontiers in Genetics | www.frontiersin.org 10 March 2015 | Volume 6 | Article 81
Tailford et al. Bacterial mucin degradation
BbhII, specific for GlcNAcβ1,3Galβ1-R (Miwa et al., 2010).
Although GH2 is a very common glycosidase present in intestinal
bacteria, the presence of membrane bound β-galactosidases
is limited to several bifidobacterial strains. In contrast to β-
galactosidases, GH20 β-N-acetylhexosaminidases are relatively
rare in the genome of enteric bacteria (Miwa et al., 2010). An
unusual activity was reported for a GH20 enzyme from Pre-
votella strain RS2; the enzyme cleaved terminal 6-SO3-GlcNAc
from sulfated mucin glycans, representing a novel activity within
the GH20 family (Rho et al., 2005). Other sulfatases have also
been characterized (Table S1), but since these do not recognize
glycosidic bonds, they are not classified in the CAZy database.
Few GH84 and GH85 β-N-acetylglucosaminidases have been
characterized so far and although these enzymes have been impli-
cated in mucin metabolism [e.g., C. perfringens str 13 (Ficko-
Blean and Boraston, 2005), and B. longumNCC2705 (Schell et al.,
2002)], none have been enzymatically characterized using mucin
glycans as substrates (Table S1). The crystal structure of the GH84
from B. thetaiotaomicron VPI-5482 has been elucidated (Dennis
et al., 2006), but the activity of this enzyme has been studied with
protein-O-GlcNAc and not mucin glycans.
The GH89, α-N-acetylglucosaminidase (AgnC), from C. per-
fringens (str 13124) has been studied structurally (Ficko-Blean
et al., 2008; Ficko-Blean and Boraston, 2012b) and the highly sim-
ilar enzyme from C. perfringens str 13 has been demonstrated
to be active against PGM and cell surface mucin (from adeno-
carcinoma AGSα4GnT cells stably expressing GlcNAcα1,4Gal as
O-glycans on the cell surface). These studies suggest a role for
AgnC in the release of terminal GlcNAc (Fujita et al., 2011) from
“Class III” gastroduodenal mucins (Nakajima et al., 2003), similar
to GH129 (above).
Impact of Mucin-Degrading Bacteria on
Human Gut Health and Disease
Spatial and Temporal Colonization
Members of the human gut microbiota strains typically display
a subset of glycan-degrading phenotypes that equip them to
target just part of the overall glycan repertoire present at cer-
tain times or locations (Koropatkin et al., 2012). The ability of
mucin-degrading bacteria to forage on the diversity and abun-
dance of glycans present in GI mucus may have a role in early
colonization by providing some bacteria with an endogenous
source of nutrients before the introduction of dietary glycans.
Due to the chemical similarity of HMOs and O-linked mucin
glycans, bacteria have developed common strategies for degrad-
ing these complex carbohydrates, as reported in B. thetaiotaomi-
cron and Bifibobacteria (Turroni et al., 2010; Marcobal et al.,
2011). Bifidobacteria possess two distinct pathways for assimila-
tion of O-glycans on gastroduodenal and intestinal mucins; GH
homologs involved in mucin and HMO utilization are conserved
in infant-associated bifidobacteria, suggesting a significant role
for their adaptation within the infant gut (Turroni et al., 2010;
Kiyohara et al., 2012). A B. thetaiotaomicron deletion mutant
for O-glycan utilization used in a germ-free mouse colonization
experiments was outcompeted >200-fold relative to the wild-
type and the complemented-mutant bacteria and pre-weaned
pups selectively retained the mucin-degrading wild-type and
complemented strains (Martens et al., 2008), suggesting that
mucin degradation may confer an ecological advantage to the
bacteria inhabiting the mammalian GI tract. R. gnavus is an early
infant colonizer of the human intestine (Favier et al., 2002) and
in the top 15 species showing abundance in both adult and infant
gut-enriched genes, in line with its adaptation to the intestinal
habitat throughout life (Hattori and Taylor, 2009). A recent study
showed that R. gnavus was predominant in breast milk-/goat
milk-fed microbiotas compared to a more diverse collection of
Lachnospiraceae in cow milk-fed babies (Tannock et al., 2013).
Taken together, these findings suggest that the ability to forage on
mucin glycans in the infant GI tract may contribute to the ability
of gut bacteria species to establish early colonization (Koropatkin
et al., 2012).
Microbial communities that are strongly associated with the
mucosa are different from those that are frequently sampled from
the feces (Ouwerkerk et al., 2013), with an overrepresentation
of bacteria that degrade mucins (see above). A study using
germ-free mice colonized with Escherichia coli and the mucin
degrader B. fragilis, revealed that only B. fragilis penetrates the
mucus layer in the mouse colon (Huang et al., 2011). Therefore,
the ability to metabolize mucin O-linked glycans is likely to
be a key factor in determining which bacteria species adapt to
the mucosal environment for in vivo colonization of animals.
Mucosa-associated bacteria, due to their intimate proximity to
the host epithelium, are likely to play a significant role in human
health and disease. Indeed the intestinal epithelium directly
benefits from the products of microbial metabolism by absorbing
short-chain fatty acids (SCFAs) such as butyrate, propionate,
and acetate which have been demonstrated to reduce the risk of
GI disorders. Nutritional strategies such as the administration
of prebiotics can modulate the composition of the mucosal
microbes, shifting mucin degradation to distal regions, where
mucin-degrading bacteria may produce metabolites influencing
the host (Van Den Abbeele et al., 2011).
Inflammation and Metabolic Syndromes
During the past decade there has been increasing focus on
gut microbiota as an influential factor on inflammatory dis-
ease development in both humans and animals. Inflammatory
bowel disease (IBD) is characterized by an increase in total
mucosa-associated bacteria (Schultsz et al., 1999). IBD patients
have a disproportionate representation of mucin-degrading bac-
teria. A ∼100-fold and >4-fold increase in R. torques and
R. gnavus, respectively, was observed in macroscopically- and
histologically-normal intestinal epithelia in cases of both Crohn’s
disease (CD) and ulcerative colitis (UC) (Png et al., 2010). In
contrast, the most abundantly detected mucolytic bacterium in
controls,A.muciniphila, was reducedmany fold in CD and inUC
(Png et al., 2010). Comparison between ileal mucosa samples of
healthy individuals with patients suffering from ileal CD revealed
an increased abundance of R. gnavus with a reduced abun-
dance of F. prausnitzii in CD patients (Willing et al., 2010). The
same findings were observed in fecal samples from CD patients
compared to unaffected controls (Sokol et al., 2009; Joossens
et al., 2011). A reduction of F. prausnitzii in mucosa-associated
microbiota of CD patients is associated with a higher risk of
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postoperative recurrence of ileal CD (Sokol et al., 2008). In
contrast, high prevalence of aggregative, adherent Escherichia
coli strains has been reported in the mucosa-associated micro-
biota of CD patients (Darfeuille-Michaud et al., 2004; Thomazini
et al., 2011). In CD and UC patients only the mucosa associ-
ated population of E. coli is augmented and the proliferation
is prominent in the ileum of CD and rectum and sigmoid of
both UC and CD patients which are sites where the lesions
are usually observed (De Souza et al., 2012). A recent study
examining CD, UC, and irritable bowel syndrome (IBS) patients
showed that mucosa-associated F. prausnitzii and E. coli co-
abundance can distinguish IBS and IBD phenotypes (Lopez-Siles
et al., 2014). An earlier study reported that colonic biopsies
from CD-aﬄicted patients compared with biopsies from nor-
mal control subjects had an increase in anaerobic bacteria; in the
small bowel, CD patients had an increase in the R. gnavus sub-
group with a decrease in the Clostridium leptum and Prevotella
nigrescens subgroups (Prindiville et al., 2004). A different pat-
tern was observed in patients with active UC, where R. gnavus
was found abundantly present in the colonic mucosa of healthy
subjects but lost during active UC (Nishikawa et al., 2009). It
has been hypothesized that increased mucin-degrading bacte-
ria in IBD provide increased substrate to sustain non-mucolytic
mucosa-associated bacteria, which could explain the increased
total mucosa-associated bacteria in IBD. The mucin degrader
R. torques is also frequently associated with conditions such as
IBS (Malinen et al., 2010). Altogether these studies point toward
an important role of mucin-degrading bacteria in modulating
gut inflammatory response at the mucosal surface. It has been
proposed that excessive mucin degradation by intestinal bacteria
may contribute to intestinal disorders, as access of luminal anti-
gens to the intestinal immune system is facilitated (Ganesh et al.,
2013). However, it is not known whether all mucin-degraders
have the same effect. For example A. muciniphila may possess
anti-inflammatory properties, as a high proportion of the bac-
teria has been correlated to protection against inflammation in
diseases such as type 1 diabetes mellitus (Hansen et al., 2012),
IBD (Png et al., 2010), atopic dermatitis (Candela et al., 2012),
autism (Wang et al., 2011), type 2 diabetes mellitus (Ellekilde
et al., 2014), and obesity (Everard et al., 2013; Le Chatelier
et al., 2013). A. muciniphila treatment can reverse fat gain, serum
lipopolysaccharide (LPS) levels, gut barrier function, and insulin
resistance. With regards to mucus, an increase in A. muciniphila
has been shown to correlate with an increase in the number of
goblet cells, potentially underlying the improved glucose profiles
seen after A. muciniphila administration (Shin et al., 2014). In
light of these findings, future work is warranted to gain a bet-
ter understanding of the role of mucin-degraders in metabolic
syndromes.
Infection
The ability of enteric pathogens to thrive within the gut mucosal
environment is intimately linked to the glycan metabolism of
mucin-degrading bacteria. S. typhimurium accesses fucose and
sialic acid within the lumen of the gut in a microbiota-dependent
manner, and genetic ablation of the respective catabolic pathways
reduces its competitiveness in vivo (Ng et al., 2013). Similarly,
C. difficile expansion is aided by microbiota-induced elevation of
sialic acid levels in vivo. Colonization of gnotobiotic mice with
a sialidase-deficient mutant of B. thetaiotaomicron reduces free
sialic acid levels resulting in C. difficile down-regulating its sialic
acid catabolic pathway and exhibiting impaired expansion. These
effects were reversed by exogenous dietary administration of free
sialic acid (Ng et al., 2013). Furthermore, A. muciniphila was
shown in gnotobiotic mice to exacerbate S. typhimurium-induced
intestinal inflammation by its ability to disturb hostmucus home-
ostasis (Ganesh et al., 2013). The GI pathogen, enterohaemor-
rhagic E. coli (EHEC), encodes a two-component system, termed
FusKR, which responds to fucose and represses expression of
virulence genes. During growth in mucin, B. thetaiotaomicron
releases fucose from mucin, thereby activating the FusKR signal-
ing cascade, modulating the virulence gene expression of EHEC
(Pacheco et al., 2012). Taken together these studies indicate that
mucin-derived monosaccharides made available by the micro-
biota profoundly influence the expansion of enteric pathogens
within the gut.
Conclusions
Bacterial-mediatedmucinglycan catabolism is an important com-
ponent in gut colonization which impacts on microbiota ecology
and gut health. Based on the studies reported in this review, gut
bacteria strains appear to rarely produce the complete set of gly-
cosidasesnecessary for thedegradationofmucinglycans into their
constituentmonosaccharides and it is thus likely that in vivo com-
plete degradation of mucins in the gut relies on the cooperative
action of several microbial species. In recent years an alteration
of the gut microbiota structure and function has been associated
with an increasing number of diseases outside and inside the gut
anddiet has emerged as one of themost important factors believed
to affect the compositionandactivity of the gutmicrobiome.How-
ever, the systematic contributionofmucin-degraders in guthome-
ostasis and dysbiosis has not yet been investigated. One of the
reasons is that so far only a fewbacteria species have been reported
and characterized as “mucin-degraders.” Expanding our knowl-
edge into the nature of different mucin-degrading bacteria and
their differential roles in the GI tract is important to help develop
new therapeutic approaches aimed at restoring eubiosis in inflam-
matory conditions and preventing infectious diseases caused by
enteric pathogens.
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